Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones

Achillion Pharmaceuticals (Nasdaq: ACHN ) today reported progress on the Company's portfolio of proprietary compounds for the treatment of chronic hepatitis C (HCV) and outlined its 2014 milestones. "We believe that we have the broad portfolio of HCV compounds necessary to succeed in achieving our primary goal of developing commercially